 ContraFect Corporation CFRX, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents DLAs, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that that the U.S. Food and Drug Administration FDA has granted Breakthrough Therapy designation to exebacase for the treatment of MRSA bloodstream infections bacteremia, including right-sided endocarditis, when used in addition to standard-of-care SOC anti-staphylococcal antibiotics in adult patients. 